Trial Profile
Phase II Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 04 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Feb 2022 Primary endpoint (To define the pathologic response rate (pT2) has been met according to the results presented at the 2022 Genitourinary Cancers Symposium